Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2022 Net Income-$40.11M-$40.11MN/M vs Q3 2022 EPS Diluted$0.86$0.86N/M vs Q3 2022 Operating Income-$18,337,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
derived
ended Sep 30, 2023 · filed Nov 9, 2023 · 40 d after period end